Skip to Main Content

++

INTRODUCTION

++

dexlansoprazole (deks-lan-soe-pra-zole)

Kapidex

Classification

Therapeutic: antiulcer agents

Pharmacologic: proton-pump inhibitors

++
Indications
++

Healing/maintenance of healing of erosive esophagitis (EE). Treatment of heartburn from nonerosive gastroesophageal reflux disease (GERD).

++
Action
++

Binds to an enzyme in the presence of acidic gastric pH, preventing the final transport of hydrogen ions into the gastric lumen. Therapeutic Effects: Diminished accumulation of acid in the gastric lumen, with lessened acid reflux.

++
Adverse Reactions/Side Effects
++

GI: abdominal pain, diarrhea, flatulence, nausea, vomiting.

++

PHYSICAL THERAPY IMPLICATIONS

++
Examination and Evaluation
++

  • Monitor improvements in GI symptoms (gastritis, heartburn, and so forth) to help determine if drug therapy is successful.

++
Interventions
++

  • In cases of NSAID-induced gastritis, implement appropriate manual therapy techniques, physical agents, and therapeutic exercises to reduce pain and decrease the need for aspirin and other NSAIDs.

++
Patient/Client-Related Instruction
++

  • Advise patient to avoid alcohol and foods that may cause an increase in GI irritation.

  • Instruct patient to report bothersome or prolonged GI side effects such as nausea, vomiting, diarrhea, flatulence, and abdominal pain.

++
Pharmacokinetics
++

Absorption: Well absorbed following oral administration.

++

Distribution: Unknown.

++

Protein Binding: 96–99%.

++

Metabolism and Excretion: Extensively metabolized by the liver (CYP2C19 and CYP3A4 enzyme systems are involved); patients who are poor metabolizers may have higher blood levels; no active metabolites. No renal elimination.

++

Half-life: 1–2 hr.

++

Table Graphic Jump Location
Favorite Table | Download (.pdf) | Print

TIME/ACTION PROFILE (blood levels)

ROUTE ONSET PEAK* DURATION
PO unknown 1–2 hr (1st); 4–5 hr (2nd) 24 hr

*Reflects effects of delayed release capsule.

++
Contraindications/Precautions
++

Contraindicated in: Hypersensitivity; Severe hepatic impairment; Geri: Avoid nursing.

++

Use Cautiously in: Moderate hepatic impairment (daily dose should not exceed 30 mg); Safe use in children <18 yr not established.

++
Interactions
++

Drug-Drug: ↓ levels of atazanavir; do not administer concurrently. May ↓ absorption of drugs requiring acid pH for absorption, including ampicillin, digoxin, iron salts, and ketoconazole. May ↑ effect of warfarin.

++
Route/Dosage
++

PO (Adults): Healing of EE—60 mg once daily for up to 8 wk; maintenance of healing of EE—30 mg once daily for up to 6 mo; GERD—30 mg once daily for 4 wk.

++
Hepatic Impairment
++

PO (Adults): Moderate hepatic impairment—daily dose should not exceed 30 mg.

++
Availability
++

Delayed-release capsules: 30 mg, 60 mg.

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.